Chronic rhinosinusitis endotyping: Sharpening the focus on inflammation - 05/05/16
Doi : 10.1016/j.jaci.2016.03.011
Daniel L. Hamilos, MD ⁎ 
Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass
∗Corresponding author: Daniel L. Hamilos, MD, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, 55 Fruit Street, Bulfinch-422, Boston, MA 02114.Division of Rheumatology, Allergy & ImmunologyMassachusetts General Hospital55 Fruit Street, Bulfinch-422BostonMA 02114
Key words : Chronic rhinosinusitis, endotyping
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: D. L. Hamilos has received consultancy fees from Sanofi, Regeneron, Genentech, and AstraZeneca; and receives royalties from UpToDate. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 137 - N° 5
P. 1457-1459 - mai 2016 Retour au numéro
Article précédent
- Obesity and rhinitis in a nationwide study of children and adults in the United States
- Yueh-Ying Han, Erick Forno, Mudita Gogna, Juan C. Celedón
- Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1–high T cells
- Jong Hoon Kim, Young Joon Choi, Byung Ha Lee, Mi-Young Song, Chae Yeon Ban, Jihye Kim, Junsik Park, Song-Ee Kim, Tae-Gyun Kim, Su-Hyung Park, Hyoung-Pyo Kim, Young-Chul Sung, Soo-Chan Kim, Eui-Cheol Shin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?